Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome
Not Applicable
Completed
- Conditions
- Irritable Bowel Syndrome (IBS)
- Registration Number
- NCT02092402
- Lead Sponsor
- Örebro University, Sweden
- Brief Summary
The purpose of this study is to investigate the effect of fecal microbiota transplantation (FMT) on the symptoms of irritable bowel syndrome (IBS) patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS version of the gastrointestinal symptom rating scale (GSRS-IBS) 6 months
- Secondary Outcome Measures
Name Time Method Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS - severity scoring system (IBS-SSS) 6 months Effect of fecal microbiota transplantation on the general health of IBS patients using the SF-36 survey 6 months Effect of fecal transplantation on IBS patients' composition of mucosal microbiota (HITChip analysis) 2 months Effect of fecal transplantation on IBS patients' mucosal immune cell composition (lymphocyte fingerprinting using flow cytometry) 2 months Effect of fecal microbiota transplantation on the symptoms of IBS patients using the health-related quality of life questionnaire for IBS patients (IBS-QOL) 6 months Effect of fecal microbiota transplantation on the symptoms of IBS patients using the hospital and anxiety depression scale (HADS) 6 months Effect of fecal transplantation on IBS patients' visceral perception (Pain scores on the visual analogue scale during barostat procedure) 2 months Effect of fecal transplantation on IBS patients' composition of fecal microbiota (HITChip analysis) 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie FMT efficacy in IBS patients as studied in NCT02092402?
How does FMT compare to standard-of-care treatments like linaclotide or rifaximin for IBS symptoms?
Are specific gut microbiota biomarkers predictive of FMT response in IBS subtypes (IBS-D, IBS-C)?
What adverse events were observed in NCT02092402 and how were they managed in IBS patients?
What combination therapies with FMT show promise for IBS treatment compared to monotherapy?
Trial Locations
- Locations (1)
University Hospital Örebro
🇸🇪Örebro, Sweden
University Hospital Örebro🇸🇪Örebro, Sweden